Atherosclerosis
Volume 205, Issue 1 , Pages 1-8 , July 2009

Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease

Received 2 October 2008 ,Revised 4 March 2009 ,Accepted 6 March 2009.

References 

  1. Petersen S, Peto V, Rayner M, et al. European cardiovascular disease statistics. London: British Heart Foundation; 2005;
  2. Diabetes prevalence. Available from International Diabetes Federation, www.idf.org. Accessed September 29, 2008.
  3. U.S. Obesity trends 1985–2007. Available from Centers for Disease Control and Prevention, www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/index.htm. Accessed September 29, 2008.
  4. Chinetti-Gbaguidi G, Fruchart JC, Staels B. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. Curr Opin Pharmacol. 2005;5:177–183
  5. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem. 1997;272:28210–28217
  6. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336–5348
  7. Prieur X, Coste H, Rodriguez JC. The human apolipoprotein AV gene is regulated by PPARα and contains a novel FXR response element. J Biol Chem. 2003;278:25468–25480
  8. Staels B, Vu-Dac N, Kosykh V, et al. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl co-enzyme A oxidase. J Clin Invest. 1995;95:705–712
  9. Raspé E, Duez H, Mansén A, et al. Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription. J Lipid Res. 2002;43:2172–2179
  10. Tomiyasu K, Walsh BW, Ikewaki K, et al. Differential metabolism of human VLDL according to content of ApoE and ApoC-III. Arterioscler Thromb Vasc Biol. 2001;21:1494–1500
  11. Hiukka A, Fruchart-Najib J, Fruchart JC, et al. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein species in type 2 diabetes. Diabetologia. 2005;48:1207–1215
  12. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–2093
  13. Chinetti G, Gbaguidi GF, Griglio S, et al. CLA-SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation. 2000;101:2411–2417
  14. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53–58
  15. Chinetti G, Lestavel S, Fruchart JC, Clavey V, Staels B. Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ Res. 2003;92:212–217
  16. Chinetti-Gbaguidi G, Rigamonti E, Helin L, et al. Peroxisome proliferator-activated receptor α controls cellular cholesterol trafficking in macrophages. J Lipid Res. 2005;46:2717–2725
  17. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not PPARgamma activators. Nature. 1998;393:790–793
  18. Marx N, Sukhova G, Collins T, Libby P, Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule 1 expression in human endothelial cells. Circulation. 1999;99:3125–3131
  19. Neve BP, Corseaux D, Chinetti G, et al. PPARα agonists inhibit tissue factor expression in human THP-1 cells, monocytes and macrophages. Circulation. 2001;103:207–212
  20. Delerive P, De Bosscher K, Besnard S, et al. PPARα negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem. 1999;274:32048–32054
  21. Lee H, Shi W, Tontonoz P, et al. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res. 2000;87:516–521
  22. Pasceri V, Cheng JS, Willerson JT, Yeh ET . Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531–2534[Erratum in: Circulation 2001 ;104(October(16)):1992. Chang J [corrected to Cheng JS]]
  23. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85:394–402
  24. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002;122:274–280
  25. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as anti-inflammatory mediators in human T lymphocytes, implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002;90:703–710
  26. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of PPARα activators. J Biol Chem. 2000;275:36703–36707
  27. Madej A, Okopien B, Kowalski J, et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther. 1998;36:345–349
  28. Ip E, Farrell C, Robertson G, et al. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology. 2003;38:123–132
  29. Fernández-Miranda C, Pérez-Carreras M, Colina F, et al. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40:200–205
  30. Shu H, Wong B, Zhou G, et al. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocyte THP-1 cells. Biochem Biophys Res Commun. 2000;267:345–349
  31. Chinetti G, Griglio S, Antonucci M, et al. Activation of peroxisome proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273:25573–25580
  32. Neve BP, Corseaux D, Chinetti G, et al. PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001;103:207–212
  33. Nilsson B, Banfi C, Diczfalusy U, et al. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18:1679–1685
  34. Durrington PN, Mackness MI, Bhatnagar D, et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis. 1998;138:217–225
  35. Gizard F, Amant C, Barbier O, et al. PPARα inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest. 2005;115:3228–3238
  36. Kersten S, Seydoux J, Peters JM, et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest. 1999;103:1489–1498
  37. Guerre-Millo M, Gervois P, Raspé E, et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000;275:16638–16642
  38. Stienstra R, Mandard S, Patsouris D, et al. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology. 2007;148:2753–2763
  39. Yessoufou A, Atègbo JM, Attakpa E, et al. Peroxisome proliferator-activated receptor-alpha modulates insulin gene transcription factors and inflammation in adipose tissues in mice. Mol Cell Biochem. 2008;(November):[Epub ahead of print]
  40. Tsuchida A, Yamauchi T, Takekawa S, et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 2005;54:3358–3370
  41. Cholesterol Treatment Trialists’ (CTT) CollaboratorsKearney PM, Blackwell PM, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125
  42. Barter PJ, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310
  43. Miller M, Cannon CP, Murphy SA, et al. PROVE-IT TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–730
  44. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418
  45. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med. 2002;162:2597–2604
  46. The BIP Study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The bezafibrate infarction prevention (BIP) study. Circulation. 2000;102:21–27
  47. Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165:1154–1160
  48. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237–1245
  49. Tenkanen L, Mantarri M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation. 1995;92:1779–1785
  50. Keech A, Simes RJ, Barter P, et al. The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861
  51. Scott R, O’Brien R, Fulcher G, et al. The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care. 2008;published on-line November 4, 2008
  52. DAIS Investigators . DAIS: effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905–910
  53. Bloomgarden ZT. Second world congress on the insulin resistance syndrome. Diabetes Care. 2005;28:2073–2080
  54. Coban E, Sari R. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients. Endocr Res. 2004;30:343–349
  55. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95:462–468
  56. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin. Am J Cardiol. 2005;95:120–122
  57. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002;30:1280–1287
  58. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393
  59. Keech AC, Mitchell P, Summanen PA, et al. FIELD Study Investigators, effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–1697
  60. Sato M. Peroxisome proliferator activated receptor ligands and angiogenesis. Nippon Rinsho. 2005;63:603–608
  61. Panigrahy D, Kaipainen A, Huang S, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA. 2008;105:985–990
  62. Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr Med Chem. 2006;13:3307–3317
  63. Kim J, Ahn JH, Yu YS, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res. 2007;84:886–893
  64. Kamijo Y, Hora K, Tanaka N, et al. Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules. J Am Soc Nephrol. 2002;13:1691–1702
  65. Duez H, Lefebvre B, Poulain P, et al. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor α modulation. Arterioscler Thromb Vasc Biol. 2005;25:585–591
  66. Fruchart JC. Novel peroxisome proliferator activated-receptor-α agonists. Am J Cardiol. 2007;100(suppl):41N–46N
  67. Colman P, Rajamani K, Li L-P et al. Benefits of long-term fenofibrate therapy on amputations in type 2 diabetes mellitus in the FIELD trial. Presented at the European Association for the study of Diabetes (EASD), Rome, September 2008.

PII: S0021-9150(09)00214-7

doi: 10.1016/j.atherosclerosis.2009.03.008

Atherosclerosis
Volume 205, Issue 1 , Pages 1-8 , July 2009

Article Tools

* Image Usage & Resolution